UPDATE: Goldman Sachs Starts Nautilus Biotechnology (NAUT) at Neutral

(Updated - August 4, 2021 5:04 AM EDT)

Goldman Sachs analyst Matthew Sykes initiates coverage on Nautilus Biotechnology (NASDAQ: NAUT) with a Neutral rating and a price target of $10.00.

The analyst comments "We initiate coverage on NAUT with a Neutral rating and $10 price target. NAUT is a proteomics company developing and commercializing a novel technology for the accurate measurement of the complete human proteome. NAUT technology uses machine learning and microchip materials science to achieve unprecedented scale of single molecule resolution. We like NAUT for three reasons: 1) sizeable $25B existing TAM ripe for disruption, 2) rapid proteomic market growth, and 3) strong margin outlook. That said, we are waiting for more data on system performance as well as commercial execution before we become more positive."

For an analyst ratings summary and ratings history on Nautilus Biotechnology click here. For more ratings news on Nautilus Biotechnology click here.

Shares of Nautilus Biotechnology closed at $7.65 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• SL Green Realty (SLG) PT Lowered to $45 at Jefferies
• Bunge (BG) PT Raised to $122 at Citi